Perspectives on contraceptive implant use in women living with HIV in Cape Town, South Africa: a qualitative study among primary healthcare providers and stakeholders.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
26 Jul 2019
Historique:
received: 27 09 2018
accepted: 12 07 2019
entrez: 28 7 2019
pubmed: 28 7 2019
medline: 28 10 2019
Statut: epublish

Résumé

This study explored primary healthcare provider and HIV/contraception expert stakeholder perspectives on South Africa's public sector provision of contraceptive implants to women living with HIV. We investigated the contraceptive service-impact of official advice against provision of implants to women using the HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014. Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or contraception. In-depth interviews and a group discussion explored South Africa's implant introduction and implant provision to women living with HIV. Data was analysed using an inductive thematic analysis approach. Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing to providers' decisions to suspend provision of the implant to women living with HIV included: inadequate initial and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider unwillingness to risk harming clients and concerns about professional liability; and other pressures related to provider capacity. All South African women, including those living with HIV, should have access to the full range of contraceptive options for which they are medically eligible. Changing guidance should be initiated and communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in particular implant provision for women with HIV, is needed. These recommendations accord with the right of women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including informed contraceptive choice and access to the contraceptive implant.

Sections du résumé

BACKGROUND BACKGROUND
This study explored primary healthcare provider and HIV/contraception expert stakeholder perspectives on South Africa's public sector provision of contraceptive implants to women living with HIV. We investigated the contraceptive service-impact of official advice against provision of implants to women using the HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014.
METHODS METHODS
Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or contraception. In-depth interviews and a group discussion explored South Africa's implant introduction and implant provision to women living with HIV. Data was analysed using an inductive thematic analysis approach.
RESULTS RESULTS
Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing to providers' decisions to suspend provision of the implant to women living with HIV included: inadequate initial and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider unwillingness to risk harming clients and concerns about professional liability; and other pressures related to provider capacity.
CONCLUSIONS CONCLUSIONS
All South African women, including those living with HIV, should have access to the full range of contraceptive options for which they are medically eligible. Changing guidance should be initiated and communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in particular implant provision for women with HIV, is needed. These recommendations accord with the right of women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including informed contraceptive choice and access to the contraceptive implant.

Identifiants

pubmed: 31349786
doi: 10.1186/s12889-019-7312-1
pii: 10.1186/s12889-019-7312-1
pmc: PMC6660962
doi:

Substances chimiques

Alkynes 0
Benzoxazines 0
Contraceptive Agents, Female 0
Cyclopropanes 0
Drug Implants 0
efavirenz JE6H2O27P8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1003

Subventions

Organisme : Joint Cape Higher Education Consortium- Western Cape Government Grant (ZA)
ID : Awarded to the School of Public Health at University of the Western Cape and the School of Public Health and Family Medicine at University of Cape Town

Références

Sex Transm Dis. 2006 Jun;33(6):350-6
pubmed: 16505747
Bull World Health Organ. 2009 Nov;87(11):833-9
pubmed: 20072768
Obstet Gynecol. 2011 Mar;117(3):705-19
pubmed: 21343774
Stud Fam Plann. 2010 Dec;41(4):241-50
pubmed: 21465725
AIDS. 2014 Mar 13;28(5):791-3
pubmed: 24401645
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):378-85
pubmed: 24798768
Glob Health Sci Pract. 2013 Mar 21;1(1):11-7
pubmed: 25276512
Glob Health Sci Pract. 2013 Jul 26;1(2):203-12
pubmed: 25276533
Lancet HIV. 2015 Nov;2(11):e454-5
pubmed: 26520921
Lancet HIV. 2015 Nov;2(11):e474-82
pubmed: 26520927
AIDS. 2015 Nov;29(17):2353-9
pubmed: 26544706
J Int AIDS Soc. 2017 May 11;20(1):21396
pubmed: 28530033
S Afr Med J. 2017 Oct 01;107(10):815-821
pubmed: 29397680
S Afr Med J. 2017 Oct 01;107(10):822-826
pubmed: 29397681
S Afr Med J. 2017 Oct 01;107(11):933-938
pubmed: 29399422
S Afr Med J. 2017 Nov 01;107(11):939-944
pubmed: 29400025

Auteurs

Anna Brown (A)

School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. annajhbrown@gmail.com.

Jane Harries (J)

Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Diane Cooper (D)

Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
School of Public Health, University of the Western Cape, Cape Town, South Africa.

Chelsea Morroni (C)

Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.
Botswana UPenn Partnership, Gaborone, Botswana.
Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH